Biosample Hub

💡 𝗙𝗿𝘂𝗰𝘁𝗼𝘀𝗲 𝗮𝗻𝗱 𝗖𝗮𝗻𝗰𝗲𝗿: 𝗔 𝗦𝘂𝗿𝗽𝗿𝗶𝘀𝗶𝗻𝗴 𝗖𝗼𝗻𝗻𝗲𝗰𝘁𝗶𝗼𝗻 Emerging research highlights an intriguing link between dietary fructose and tumor growth. A study from Washington University reveals that fructose, when metabolized by the liver, produces lipids that cancer cells utilize to grow. This process emphasizes the liver's critical role in transforming fructose into tumor-supportive nutrients rather than cancer cells directly consuming fructose. This work is published in Nature in the paper, “Dietary fructose enhances tumor growth indirectly via interorgan lipid transfer.” https://lnkd.in/eMysMdkD It shows that dietary fructose promotes tumor growth in animal models of melanoma, breast cancer, and cervical cancer after being converted in the liver. 𝑲𝒆𝒚 𝒕𝒂𝒌𝒆𝒂𝒘𝒂𝒚𝒔: For those battling cancer, reducing fructose intake might be beneficial. This discovery could also inspire therapies targeting the metabolism of healthy cells to inhibit tumor progression. https://lnkd.in/eUPKF35E

💡𝗘𝘅𝗰𝗶𝘁𝗶𝗻𝗴 𝗣𝗼𝘁𝗲𝗻𝘁𝗶𝗮𝗹 𝗳𝗼𝗿 𝗚𝗟𝗣-𝟭𝘀 𝗶𝗻 𝗔𝗹𝘇𝗵𝗲𝗶𝗺𝗲𝗿’𝘀 𝗧𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁 💡 Recent studies suggest that GLP-1 receptor agonists—popular for treating diabetes and obesity—may help reduce Alzheimer's risk and slow cognitive decline. Novo Nordisk's semaglutide and liraglutide have shown encouraging results. For example, one recent paper, published in Alzheimer’s and Dementia in October, described a real-world study showing that patients with type 2 diabetes taking semaglutide had a 40% to 70% reduction in the risk of Alzheimer’s disease diagnosis. Phase III trials are anticipated to yield critical insights in 2025. This research highlights the connection between metabolic disorders and Alzheimer's, sparking hope for new preventative and therapeutic strategies. https://lnkd.in/eramY5KS

𝗗𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 𝗼𝗳 𝗮 𝗕𝗶𝗼𝗯𝗮𝗻𝗸 𝗼𝗳 𝗨𝘃𝗲𝗮𝗹 𝗠𝗲𝗹𝗮𝗻𝗼𝗺𝗮 𝗣𝗮𝘁𝗶𝗲𝗻𝘁-𝗗𝗲𝗿𝗶𝘃𝗲𝗱 𝗢𝗿𝗴𝗮𝗻𝗼𝗶𝗱𝘀 (𝗣𝗗𝗢𝘀) 𝘁𝗼 𝗦𝘂𝗽𝗽𝗼𝗿𝘁 𝗧𝗿𝗮𝗻𝘀𝗹𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵. Uveal melanoma (UM) is the most common primary malignancy of the eye in adults. Unfortunately, a major limitation to preclinical drug screening for UM is a lack of human disease models representing the entire clinical and molecular spectrum of the disease. As described in this report, researchers from various institutions including Mayo Clinic in Rochester, Wills Eye Hospital in Philadelphia, and Deakin Uni in Australia, have collaborated to create a multi-center biobank including PDOs from 40 different patient tumors. These PDOs show promise for translational research because they retained clinically relevant mutations and molecular markers from the primary tumors, and displayed similar gene expression profiles and well-validated clinical prognostic markers of the disease. They also retained tumorigenic capacity in an in vivo model. https://lnkd.in/eRK2Y9k9 #biobank #biobanking #pdo #organoids

𝗜𝗻𝗶𝘁𝗶𝗮𝘁𝗶𝘃𝗲 𝘁𝗼 𝗰𝗿𝗲𝗮𝘁𝗲 𝘁𝗵𝗲 𝘄𝗼𝗿𝗹𝗱'𝘀 𝗳𝗶𝗿𝘀𝘁 𝗹𝗮𝗿𝗴𝗲-𝘀𝗰𝗮𝗹𝗲 𝗲𝗽𝗶𝗴𝗲𝗻𝗲𝘁𝗶𝗰 𝗱𝗮𝘁𝗮𝘀𝗲𝘁 Oxford Nanopore Technologies, in collaboration with UK Biobank, is set to create the world's first large-scale epigenetic dataset. This pioneering research aims to map epigenetic modifications across 50,000 samples, with a focus on major diseases like cancer and neurological disorders. The project leverages Oxford Nanopore's advanced DNA/RNA sequencing technology, which provides a comprehensive view of up to 98% of methylation markers across the genome. This is a significant leap from the 3% coverage offered by microarrays, opening up new possibilities for disease detection, diagnosis, and treatment. This initiative could revolutionize healthcare by enabling disease risk screening, early-stage detection, and the development of more precise diagnostics. By capturing nearly the entire epigenome, researchers will gain unprecedented insights into disease mechanisms, potentially leading to targeted treatments for a range of conditions. #genomics #healthcare #innovation #epigenetics #diseaseprevention https://lnkd.in/eUgBV8ku

🔬🧪 Are you passionate about therapeutics and diagnostics research and development? Do you want to stay updated with the latest in drug discovery, biomarker development, and more? Join our LinkedIn group, "Drug Targets and Biomarkers "! 🎯🧬 Here's what you can expect from our active community: 📊 Market Reports: Get insights into the current trends and future projections in the industry. 🖥️ Webinars: Learn from experts in the field and enhance your knowledge. 📰 Newsletters & Blogs: Stay updated with the latest news and opinions in the field. 🔬 Research News: Discover groundbreaking research and developments. 🏢 Company News: Know what's happening in leading companies in the industry. 👥 Personal News & Opinions: Share your thoughts and connect with like-minded professionals. 🤝 Event Shoutouts: Network with professionals and make valuable connections. 🏆 Achievements & Awards: Celebrate the success of our members and get inspired. We are proud to wear the LinkedIn 𝗔𝗰𝘁𝗶𝘃𝗲 𝗚𝗿𝗼𝘂𝗽 badge, indicating our commitment to fostering a vibrant and engaging community. Join us today and be part of the conversation shaping the future of therapeutics and diagnostics! 💡🌐 𝑪𝒍𝒊𝒄𝒌 𝒉𝒆𝒓𝒆 𝒕𝒐 𝒋𝒐𝒊𝒏: https://lnkd.in/eNMfSXi

📅 Date: Thursday 12th December @ 3pm CET. Free of charge. 𝗪𝗲𝗯𝗶𝗻𝗮𝗿 𝗼𝗻 𝗡𝗮𝘃𝗶𝗴𝗮𝘁𝗶𝗻𝗴 𝘁𝗵𝗲 𝗜𝗻𝘁𝗲𝗿𝗻𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝗥𝗲𝗴𝘂𝗹𝗮𝘁𝗶𝗼𝗻𝘀 𝗳𝗼𝗿 𝗦𝗵𝗶𝗽𝗺𝗲𝗻𝘁 𝗼𝗳 𝗕𝗶𝗼𝗹𝗼𝗴𝗶𝗰𝗮𝗹 𝗥𝗲𝘀𝗼𝘂𝗿𝗰𝗲𝘀. Join us for an insightful presentation by Romain Belot MSc, Biobanking Advisor at Biosample Hub, as we delve into the complexities of international regulations governing the shipment of biological resources. 𝑻𝒐 𝒓𝒆𝒔𝒆𝒓𝒗𝒆 𝒚𝒐𝒖𝒓 𝒑𝒍𝒂𝒄𝒆, 𝒃𝒐𝒐𝒌 𝒉𝒆𝒓𝒆: https://lnkd.in/e2GwmS8M 🔍 Key Highlights: ➡️ European Regulations: Understanding GDPR and CNIL requirements for data protection and biospecimen transfer. ➡️ U.S.A Regulations: Compliance with HIPAA, FDA guidelines, and import regulations. ➡️ Transport Regulations: Adhering to IATA Dangerous Goods Regulations for safe packaging and transport. ➡️ Non-Human Genetic Biological Resources: Navigating the Nagoya Protocol for access and benefit-sharing. Don't miss this opportunity to enhance your knowledge and ensure compliance with international standards!

𝗕𝗶𝗼𝗯𝗮𝗻𝗸𝗶𝗻𝗴 𝘄/ 𝗴𝗲𝗻𝗲𝘁𝗶𝗰𝘀 𝘀𝗵𝗮𝗽𝗲𝘀 𝗽𝗿𝗲𝗰𝗶𝘀𝗶𝗼𝗻 𝗺𝗲𝗱𝗶𝗰𝗶𝗻𝗲 & 𝗴𝗹𝗼𝗯𝗮𝗹 𝗵𝗲𝗮𝗹𝘁𝗵 Biobanks are predominantly located in Western Europe and North America, leading to an overrepresentation of European ancestries in precision medicine research. The article reviews global biobanks from a genetics perspective, discussing their design limitations, ongoing initiatives to diversify genomics research, and strategies to ensure equitable benefits from biobank-based research for all populations. Review Article - Published: 20 November 2024 https://lnkd.in/e_BP_6MT

𝗔𝗜 𝗨𝗻𝗹𝗼𝗰𝗸𝘀 𝗖𝗮𝗻𝗰𝗲𝗿 𝗦𝗲𝗰𝗿𝗲𝘁𝘀: 𝗗𝗲𝗰𝗼𝗱𝗶𝗻𝗴 𝗚𝗲𝗻𝗲 𝗘𝘅𝗽𝗿𝗲𝘀𝘀𝗶𝗼𝗻 𝗯𝘆 𝗜𝗺𝗮𝗴𝗲 𝗔𝗻𝗮𝗹𝘆𝘀𝗶𝘀 𝗼𝗳 𝗛&𝗘 𝗦𝘁𝗮𝗶𝗻𝗲𝗱 𝗧𝗶𝘀𝘀𝘂𝗲 𝗦𝗲𝗰𝘁𝗶𝗼𝗻𝘀 Exciting news in the field of cancer research! A new study published in Nature Communications this month, introduces 𝑺𝑬𝑸𝑼𝑶𝑰𝑨, an artificial intelligence-powered computational program that can predict the activity of thousands of genes within tumor cells based only on standard microscopy images of the biopsy. Developed using 7584 tumor samples across 16 cancer types, 𝑺𝑬𝑸𝑼𝑶𝑰𝑨 has shown promising results in predicting genes associated with key cancer processes. The researchers also developed a 272-gene signature that predicts the risk of breast cancer recurrence, demonstrating the model's potential in personalized cancer management. The study highlights the superior performance of 𝑺𝑬𝑸𝑼𝑶𝑰𝑨 compared to other existing architectures, marking a significant step forward in the use of AI in cancer research and treatment. https://lnkd.in/exarCWnW

🌟 𝗖𝗼𝗹𝗼𝗿𝗲𝗰𝘁𝗮𝗹 𝗖𝗮𝗻𝗰𝗲𝗿 𝗣𝗿𝗼𝗴𝗿𝗲𝘀𝘀𝗶𝗼𝗻, 𝗦𝘁𝗿𝗲𝘀𝘀 & 𝘁𝗵𝗲 𝗠𝗶𝗰𝗿𝗼𝗯𝗶𝗼𝗺𝗲 A link between chronic stress and the progression of colorectal cancer (CRC), is uncovered by exciting new research led by Dr Qing Li, presented at the United European Gastroenterology (UEG) conference. The study found that chronic stress can increase tumor growth and reduce beneficial gut bacteria, particularly the Lactobacillus genus, which plays a crucial role in our immune response against cancer. The team used an innovative approach involving an antibiotic cocktail and faecal microbiota transplantation to investigate this relationship. Interestingly, when mice were supplemented with Lactobacillus during chronic stress, there was a reduction in tumor formation. The team discovered that a specific strain, Lactobacillus plantarum, regulated bile acid metabolism and enhanced the function of CD8+ T cells, key players in our body’s anti-tumor immunity. The team is now planning to collect samples from CRC patients to further analyze changes in gut microbiota among individuals with and without chronic stress. This research opens up a promising therapeutic strategy for patients with stress-related CRC, combining traditional anti-tumor drugs with L. plantarum supplementation. This study highlights the importance of maintaining a healthy gut microbiota and how it could potentially strengthen our natural defenses against colorectal cancer. https://lnkd.in/eWR57ymt